+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?

Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?

Current Atherosclerosis Reports 13(1): 31-42

Much evidence supports a pivotal role for inflammation in atherosclerosis. C-reactive protein (CRP), the prototypic marker of inflammation in humans, is a cardiovascular risk marker and may also promote atherogenesis. CRP levels are increased in metabolic syndrome and hypertension and confer increased risk of cardiovascular events in patients in these subgroups. Statins have been shown to lower low-density lipoproteins and CRP independently, and reduce cardiovascular events in subjects with and without metabolic syndrome and hypertension. In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Post-JUPITER, the new guidelines will now need to consider recommending high-sensitivity CRP testing to intermediate-risk metabolic syndrome patients and those with hypertension and intermediate risk so that we can better identify candidates at greater risk and reduce cardiovascular burden in these subjects with statin therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911256

Download citation: RISBibTeXText

PMID: 21046291

DOI: 10.1007/s11883-010-0143-2

Related references

Moving toward new statin guidelines in a post-JUPITER world: principles to consider. Current Atherosclerosis Reports 11(4): 249-256, 2009

Statin therapy for low-LDL, high-hsCRP patients: from JUPITER to CORONA. Clinical Chemistry 56(4): 505-507, 2010

Statin therapy for the metabolic syndrome: the evidence base. Metabolic Syndrome and Related Disorders 7(5): 393-396, 2009

Managing the dyslipidemia of metabolic syndrome: beyond statin therapy. Metabolic Syndrome and Related Disorders 10(3): 159-160, 2012

Eligibility for statin therapy by the JUPITER trial criteria and subsequent mortality. American Journal of Cardiology 105(1): 77-81, 2010

Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?. International Journal of Cardiology 110(2): 276-277, 2005

Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Internal Medicine 175(2): 171-177, 2015

Tough questions about the value of statin therapy for primary prevention: did JUPITER miss the moon?. Journal of Managed Care Pharmacy 16(6): 417-423, 2010

Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD. International Urology and Nephrology 42(1): 133-136, 2010

Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. Journal of the American College of Cardiology 60(3): 216-223, 2012

Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome. Wmj 105(5): 22-25, 2006

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380(9841): 565-571, 2012

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Therapeutic Advances in Cardiovascular Disease 3(4): 309-315, 2009

Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment. Journal of Pharmacy Practice (): -, 2016

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376(9738): 333-339, 2010